Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | Journey Medical to join Russell 2000 and 3000 indexes | 3 | Investing.com | ||
Di | Journey Medical Corporation: Journey Medical to Join Russell 2000 and Russell 3000 Indexes | 1 | GlobeNewswire (USA) | ||
Di | Journey Medical Corp - 8-K, Current Report | 1 | SEC Filings | ||
20.06. | Journey Medicals Rosacea-Medikament zeigt Wirksamkeit unabhängig vom Gewicht | 1 | Investing.com Deutsch | ||
09.06. | Journey Medical Corporation Announces Emrosi Featured on "The Balancing Act" Airing on Lifetime TV | 2 | GlobeNewswire (USA) | ||
15.05. | Journey Medical Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
15.05. | Journey Medical GAAP EPS of -$0.18 beats by $0.06, revenue of $13.1M beats by $1.05M | 2 | Seeking Alpha | ||
JOURNEY MEDICAL Aktie jetzt für 0€ handeln | |||||
15.05. | Journey Medical outlines Emrosi launch momentum and targets expanded payer access in 2025 | 2 | Seeking Alpha | ||
14.05. | Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights | 87 | GlobeNewswire (Europe) | Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions... ► Artikel lesen | |
07.05. | Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025 | 2 | GlobeNewswire (USA) | ||
30.04. | Why Journey Medical Corporation (DERM) is Surging in 2025 | 1 | Insider Monkey | ||
03.04. | Journey Medical Corp - 8-K, Current Report | 2 | SEC Filings | ||
01.04. | Journey Medical appoints Ramsey Alloush as COO | 1 | Seeking Alpha | ||
01.04. | Journey Medical appoints new COO amid growth phase | 2 | Investing.com | ||
01.04. | Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer | 103 | GlobeNewswire (Europe) | SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses... ► Artikel lesen | |
26.03. | Journey Medical GAAP EPS of -$0.72 beats by $0.44, revenue of $56.13M misses by $0.59M | 4 | Seeking Alpha | ||
26.03. | Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights | 649 | GlobeNewswire (Europe) | FDA Approval of Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended... ► Artikel lesen | |
24.03. | Journey Medical Corporation Launches Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea | 3 | GlobeNewswire (USA) | ||
24.03. | Journey Medical Corp - 8-K, Current Report | - | SEC Filings | ||
19.03. | Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025 | 3 | GlobeNewswire (USA) |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PFIZER | 20,665 | +0,02 % | Depot Verdoppler mit Künstlicher Intelligenz: Novo Nordisk, PanGenomic Health und Pfizer zünden 2025 den Profit-Turbo | Lauf BlackRock Health Sciences steht der globale Gesundheitssektor 2025 vor einem beispiellosen Aufschwung. Nach Jahren der Volatilität durch die Pandemie soll die Branche jetzt die höchsten Gewinnzuwächse... ► Artikel lesen | |
GILEAD SCIENCES | 94,33 | -0,18 % | Assembly Biosciences: ABI-4334 erreicht Studienziel - Gilead-Entscheidung steht bevor | Assembly Biosciences (WKN: A402CB) liefert weiter ab: Mit ABI-4334 fällt der erste wichtige Readout dieses Jahres positiv aus. Das HBV-Asset galt als das unsicherste im Portfolio. Die Aktie liebäugelt... ► Artikel lesen | |
VERTEX PHARMACEUTICALS | 378,70 | +0,49 % | Vertex Pharmaceuticals Incorporated (VRTX) Benefited from the Launch of its New Drug | ||
EYEPOINT PHARMACEUTICALS | 8,400 | +1,89 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
ROCKET LAB | 30,200 | -0,10 % | Rocket Lab Corporation: Rocket Lab to Launch Electron Mission for European Space Agency's Next-Generation Navigation System | Rocket Lab Corporation (Nasdaq: RKLB) ("Rocket Lab" or the "Company"), a global leader in launch services and space systems, today announced it has been selected to launch a dedicated Electron mission... ► Artikel lesen | |
ASTRIA THERAPEUTICS | 4,720 | -0,84 % | Astria Therapeutics, Inc.: Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress | -- Q3M Arm Demonstrated 95% Mean Monthly Attack-Rate Reduction -- -- Q6M Arm Demonstrated 86% Mean Monthly Attack-Rate Reduction - -- Well-Tolerated with a Favorable Safety Profile -- --... ► Artikel lesen | |
OPKO HEALTH | 1,114 | -1,59 % | OPKO Health, Inc.: OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting | MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo... ► Artikel lesen | |
LIGAND PHARMACEUTICALS | 97,50 | 0,00 % | ROUNDUP: Ligand Pharmaceuticals Reiterates FY25 Outlook | WASHINGTON (dpa-AFX) - While reporting financial results for the first quarter on Thursday, biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND) reiterated its adjusted earnings and... ► Artikel lesen | |
JAZZ PHARMACEUTICALS | 92,32 | +1,05 % | Jazz Pharmaceuticals plc: Zepzelca (lurbinectedin) and Atezolizumab (Tecentriq) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer | Target Action (PDUFA) Date set for October 7, 2025
Application based on data from IMforte, the first Phase 3 trial demonstrating statistically significant and clinically... ► Artikel lesen | |
ROYALTY PHARMA | 30,530 | -0,39 % | Revolution Medicines, Inc.: Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with ... | Flexible funding provides $2 billion in committed capital comprised of up to $1.25 billion of synthetic royalty and up to $750 million in corporate debtCompany moving forward with independent global... ► Artikel lesen | |
CATALYST PHARMACEUTICALS | 18,655 | +0,24 % | Catalyst Pharma: Viel Wachstum für wenig Geld? | Die meisten Biotech-Aktien sind vor allem eins: hochspekulativ. Catalyst Pharma beweist jedoch, dass es auch anders geht - mit realen Gewinnen und nachhaltigem Wachstum Den vollständigen Artikel lesen... ► Artikel lesen | |
TG THERAPEUTICS | 31,890 | +1,67 % | TG Therapeutics, Inc.: TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance | First quarter 2025 BRIUMVI U.S. net revenue of $119.7 million Raises full year 2025 global net revenue target to approximately $575 million and raises full year BRIUMVI U.S. net revenue target to... ► Artikel lesen | |
CORBUS PHARMACEUTICALS | 6,350 | -7,97 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab | Combination cohort initiated following successful review of monotherapy cohortOver 100 participants dosed to-date in monotherapy cohortPriority are Head and Neck Squamous Cell Carcinoma (HNSCC) and... ► Artikel lesen | |
CATALENT | 59,93 | 0,00 % | GenSight Biologics Announces Significant Milestone in New Manufacturing Partnership with Catalent | Upstream phase of LUMEVOQ manufacturing process successfully transferred
Milestone follows successful manufacture of drug product batch to be used for named early access program (AAC) and... ► Artikel lesen | |
TALPHERA | 0,410 | +1,87 % | Talphera, Inc.: Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update | Cash and investments at March 31, 2025, as adjusted to include the proceeds from the first tranche of the private placement financing which closed on April 2, 2025... ► Artikel lesen |